Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Neuroendocrine CancerSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 105
- Registration Number
- NCT06283719
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06246695
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1
Recruiting
- Conditions
- Cervical Carcinoma
- Interventions
- Drug: ZG005 Powder for InjectionBiological: Bevacizumab
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06241235
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Drug: ZG005 Powder for Injection
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 130
- Registration Number
- NCT06239298
- Locations
- 🇨🇳
The Second Affiliated Hospital of Army Medical University, Chongqing, Chongqing, China
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT06237400
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of ZG2001 in Participants With KRAS Mutated Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Solid TumorKRAS Mutation-Related Tumors
- Interventions
- Drug: ZG2001 Tosilate Tablets
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 110
- Registration Number
- NCT06237413
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
A Study of ZG005 in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumors
- Interventions
- Biological: ZG005 Powder for Injection
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 484
- Registration Number
- NCT06233292
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06193148
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhu, Jiangsu, China
Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 52
- Registration Number
- NCT06132243
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1
Recruiting
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 54
- Registration Number
- NCT05978284
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China